Use of the Novel Therapeutic Agent Miltefosine for the Treatment of Primary Amebic Meningoencephalitis: Report of 1 Fatal and 1 Surviving Case

Jennifer R. Cope, Dennis A. Conrad, Naiomi Cohen, Manuel Cotilla, Alexandre Dasilva, Jonathan Jackson, Govinda S. Visvesvara

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Primary amebic meningoencephalitis (PAM) is a fulminant central nervous system infection caused by the thermophilic free-living ameba Naegleria fowleri. Few survivals have been documented and adequate treatment is lacking. We report 2 PAM cases, 1 fatal and 1 surviving, treated with the novel antiparasitic agent miltefosine.

Original languageEnglish (US)
Pages (from-to)774-776
Number of pages3
JournalClinical Infectious Diseases
Volume62
Issue number6
DOIs
StatePublished - Jul 10 2015

Keywords

  • Miltefosine
  • Naegleria fowleri
  • Primary amebic meningoencephalitis

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Use of the Novel Therapeutic Agent Miltefosine for the Treatment of Primary Amebic Meningoencephalitis: Report of 1 Fatal and 1 Surviving Case'. Together they form a unique fingerprint.

Cite this